Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 Against Triple-Negative Breast Cancer Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: mTORC1 and mTORC2 inhibition by Ku-0063794 could confer profound anticancer effects against cancer cells because it eliminates feedback activation of Akt. Herein, we aimed to determine anticancer effects of docetaxel and Ku-0063794, individually or in combination, against breast cancer cells, especially triple-negative breast cancer (TNBC) cells. Materials and methods: MCF-7 breast cancer and MDA-MB-231 TNBC cell lines for in vitro studies and mouse xenograft model for in vivo studies were used to investigate the effect of docetaxel, Ku-0063794, or their combination. Results: In the in vitro experiments, combination therapy synergistically reduced cell viability and induced higher apoptotic cell death in breast cancer cells than the individual monotherapies (p < 0.05). Western blot analysis and flow cytometric analysis showed that the combination therapy induced higher apoptotic cell death than the individual monotherapies (p < 0.05). In the in vivo experiment, docetaxel and Ku-0063794 combination therapy reduced the growth of MDA-MB-231 cells xenografted in the nude mice better than in the individual monotherapies (p < 0.05). Immunohistochemistry showed that the combination therapy induced the highest expression of cleaved caspase-3 and the lowest expression of Bcl-xL in the MDA-MB-231 cells xenografted in the nude mice (p < 0.05). Western blot analysis and immunofluorescence, incorporating both in vitro and in vivo experiments, consistently validated that unlike individual monotherapies, docetaxel and Ku-0063794 combination therapy significantly inhibited epithelial-mesenchymal transition (EMT) and autophagy (p < 0.05). Conclusion: These data suggest that docetaxel and Ku-0063794 combination therapy has higher anticancer activities over individual monotherapies against MDA-MB-231 TNBC cells through a greater inhibition of autophagy and EMT.
Abstract
Purpose: mTORC1 and mTORC2 inhibition by Ku-0063794 could confer profound anticancer effects against cancer cells because it eliminates feedback activation of Akt. Herein, we aimed to determine anticancer effects of docetaxel and Ku-0063794, individually or in combination, against breast cancer cells, especially triple-negative breast cancer (TNBC) cells. Materials and methods: MCF-7 breast cancer and MDA-MB-231 TNBC cell lines for in vitro studies and mouse xenograft model for in vivo studies were used to investigate the effect of docetaxel, Ku-0063794, or their combination. Results: In the in vitro experiments, combination therapy synergistically reduced cell viability and induced higher apoptotic cell death in breast cancer cells than the individual monotherapies (p < 0.05). Western blot analysis and flow cytometric analysis showed that the combination therapy induced higher apoptotic cell death than the individual monotherapies (p < 0.05). In the in vivo experiment, docetaxel and Ku-0063794 combination therapy reduced the growth of MDA-MB-231 cells xenografted in the nude mice better than in the individual monotherapies (p < 0.05). Immunohistochemistry showed that the combination therapy induced the highest expression of cleaved caspase-3 and the lowest expression of Bcl-xL in the MDA-MB-231 cells xenografted in the nude mice (p < 0.05). Western blot analysis and immunofluorescence, incorporating both in vitro and in vivo experiments, consistently validated that unlike individual monotherapies, docetaxel and Ku-0063794 combination therapy significantly inhibited epithelial-mesenchymal transition (EMT) and autophagy (p < 0.05). Conclusion: These data suggest that docetaxel and Ku-0063794 combination therapy has higher anticancer activities over individual monotherapies against MDA-MB-231 TNBC cells through a greater inhibition of autophagy and EMT.
참고문헌 (27)
- Bauer KR, "Des-criptive analysis of estrogen receptor(ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : a population-based study from the California cancer Registry", Cancer, 109, pp.1721~1728 (2007)
- Reis-Filho JS, "Triple negative tumours : a critical review", Histopathology, 52, pp.108~118 (2008)
- Dreyer G, "Triple negative breast cancer : clinical characteristics in the different histological subtypes", Breast, 22, pp.761~766 (2013)
- Kassam F, "Survival outcomes for patients with metastatic triple-negative breast cancer : implications for clinical practice and trial design", Clin Breast Cancer, 9, pp.29~33 (2009)
- Lin NU, "Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer : high incidence of central nervous system metastases", Cancer, 113, pp.2638~2645 (2008)
- Jhan JR, "Triple-negative breast cancer and the potential for targeted therapy", Pharmacogenomics, 18, pp.1595~1609 (2017)
- Murtagh G, "Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin : 10-year follow-up", Breast Cancer Res Treat, 156, pp.501~506 (2016)
- Garcia-Martinez JM, "Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin(mTOR)", Biochem J, 421, pp.29~42 (2009)
- Ali S, "Blinatumomab for acute lymphoblastic leukemia : the first bispecific T-cell engager antibody to be approved by the EMA for minimal residual disease", Oncologist, 25, pp.e709~e715 (2020)
- Sarbassov DD, "Growing roles for the mTOR pathway", Curr Opin Cell Biol, 17, pp.596~603 (2005)
- Xue M, "Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes", Exp Cell Res, 299, pp.119~127 (2004)
- Sparks CA, "Targeting mTOR : prospects for mTOR complex 2 inhibitors in cancer therapy", Oncogene, 29, pp.3733~3744 (2010)
- Jovanovic B, "A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II", III triple-negative breast cancer(TNBC) : responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67, 2017, pp.23, 4035~4045
- Feldman ME, "Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2", PLoS Biol, 7, pp.e38~ (2009)
- Ma XM, "Molecular mechanisms of mTOR-mediated translational control", Nat Rev Mol Cell Biol, 10, pp.307~318 (2009)
- Takebe N, "Breast cancer growth and metastasis : interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition", Breast Cancer Res, 13, pp.211~ (2011)
- Foroni C, "Epithelial-mesenchymal transition and breast cancer : role, molecular mechanisms and clinical impact", Cancer Treat Rev, 38, pp.689~697 (2012)
- Kowalski PJ, "E-cadherin expression in primary carcinomas of the breast and its distant metastases", Breast Cancer Res, 5, pp.R217~R222 (2003)
- Cristofani R, "Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells", Cell Death Dis, 9, pp.889~ (2018)
- Zhang J, "Docetaxel enhances lysosomal function through TFEB activation", Cell Death Dis, 9, pp.614~ (2018)
- Kim JO, "Potentiation of the anticancer effects of everolimus using a dual mTORC1", 2 inhibitor in hepatocellular carcinoma cells, 2017, pp.8, 2936~2948
- Mizushima N, "Protein turnover via autophagy : implications for metabolism", Annu Rev Nutr, 27, pp.19~40 (2007)
- Shimizu S, "Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes", Nat Cell Biol, 6, pp.1221~1228 (2004)
- Kim YC, "mTOR : a pharmacologic target for autophagy regulation", J Clin Invest, 125, pp.25~32 (2015)
- Hu F, "Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3", Cancer Lett, 416, pp.24~30 (2018)
- Lee IH, "A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy", Proc Natl Acad Sci U S A, 105, pp.3374~3379 (2008)
- 이상철, "Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy", Cancer Research and Treatment, 50(3), pp.1023~1038 (2018), 대한암학회